Dr. Ron Garren says that triple negative breast cancer is more prevalent that HER+ breast cancer and puts the incidence at around 25% of all breast cancers. The SeekingAlpha author has it pegged at 15%. Which number do you think is more accurate?
If CLDX could find a Euro partner for Rindo--not likely, it seems--would you be more inclined to invest?
Could you imagine the breast cancer drug making a big splash at ASCO?
Do you see any value in the early clinical stage CDX 1127, an antibody that targets CD27?
Market Data 
Markets 
AI
